Int J Arrhythm.  2017 Sep;18(3):137-142. 10.18501/arrhythmia.2017.022.

Stroke Prevention in Atrial Fibrillation

• Cha MJ

• KMID: 2395800
• DOI: http://doi.org/10.18501/arrhythmia.2017.022

Abstract

It is important to evaluate the risks of stroke and bleeding when screening patients with atrial fibrillation (AF), in whom anticoagulation therapy is indicated. Oral anticoagulation therapy is recommended in male AF patients with CHA₂DS₂-VASc score ≥1 and female AF patients with CHA₂DS₂-VASc score ≥2. Non-vitamin K oral anticoagulants (NOACs) are preferred over vitamin K anticoagulants in eligible patients. NOACs are contraindicated in patients with mechanical heart valves or moderate-to-severe mitral stenosis.

Keyword

Atrial Fibrillation; Stroke; Anticoagulation

MeSH Terms

Anticoagulants
Atrial Fibrillation*
Female
Heart Valves
Hemorrhage
Humans
Male
Mass Screening
Mitral Valve Stenosis
Stroke*
Vitamin K
Anticoagulants
Vitamin K